



Curriculum Vitae Europass

Personal Information

Name / Surname

Cinzia Baldessari

address

Via del Pozzo n 71, Modena, 41124

phone

Fax

E-mail

cinzia.baldessari@libero.it

Nationality

Italiana

Date of birth

26 January 1988

Sex

female

Professional experience

From 20/01/2015
To 20/01/2020

Scuola di Specialità di Oncologia at University of Modena

From 27/01/2020
To 15/07/2021

Medical director at Oncology with full-time fixed-term appointment – AOU di Modena

From 16/07/2021
ongoing

Medical director at Oncology with permanent full-time appointment – AOU di Modena

Name and
address of the
employer

Dipartimento Oncologia Ematologia (SSD Day Hospital Oncologico)
Az Ospedaliero-Universitaria Policlinico
Via del Pozzo 71, 41124 Modena
Tel 059-4224385 - Fax 059-422647

Field

Oncology

Education and training

2007
14/10/2013
11/02/2014
19/02/2014

School leaving Certificate at Liceo Classico G. Prati di Trento (TN)
Medical degree in Medicine and Surgery (full marks), at Medicine University of Verona
State exam for authorization in Medicine
Registration at 'Ordine dei Medici della Provincia di Trento'

Madrelingua

Italian

other

English

Publications

- 1) Bari A, Marcheselli R, Pozzi S, Cox MC, **Baldessari C**, Ferri P, Gobbi P, Baldini L, Tadmor T, Musto P, Federico M, Sacchi S. Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients. *Br J Haematol*. 2018 Feb;180(4):600-602. doi: 10.1111/bjh.14406.
- 2) Salati M, Pifferi M, **Baldessari C**, Bertolini F, Tomasello C, Cascinu S, Barbieri F. Stevens-Johnson syndrome during nivolumab treatment of NSCLC. *Ann Oncol*. 2018 Jan 1;29(1):283-284. doi: 10.1093/annonc/mdx640.
- 3) Tomasello C, **Baldessari C**, Napolitano M, Orsi G, Grizzi G, Bertolini F, Barbieri F, Cascinu S. Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. *Crit Rev Oncol Hematol*. 2018 Mar;123:149-161. doi: 10.1016/j.critrevonc.2018.01.013.
- 4) Salati M, **Baldessari C**, Cerbelli B, Botticelli A. Nivolumab in pretreated non-small cell lung cancer: continuing the immunolotion. *Transl Lung Cancer Res*. 2018 Apr;7(Suppl 2):S91-S94. doi: 10.21037/tlcr.2018.01.14.

- 5) Guaitoli G, **Baldessari C**, Tomasello C, Barbieri F, Cascinu S, Bertolini F, Cesinaro AM. Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease. *J Thorac Oncol*. 2018 Aug;13(8):e152-e153. doi: 10.1016/j.jtho.2018.03.022.
- 6) **Baldessari C**, Gelsomino F, Spallanzani A, Pugliese G, Reggiani Bonetti L, Bettelli S, Cascinu S. Beyond the Beyond: A Case of an Extraordinary Response to Multiple Lines of Therapy in a de novo Metastatic HER2-Negative Gastric Cancer Patient. *Gastrointest Tumors*. 2018 Sep;5(1-2):14-20. doi: 10.1159/000488983.
- 7) Salati M*, **Baldessari C***, Calabrese F, Rossi G, Pettolelli E, Grizzi G, Dominici M, Barbieri F. Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis. *Case Rep Oncol*. 2018 Sep 7;11(3):615-621. doi: 10.1159/000492666.. (*contributed equally to this work)
- 8) Guaitoli G*, **Baldessari C***, Bertolini F, Tomasello C, Cascinu S, Barbieri F. Are we ready to describe response or progression to immunotherapy in lung cancer? *Crit Rev Oncol Hematol*. 2019 Jun;138:112-119. doi: 10.1016/j.critrevonc.2019.04.002. (*contributed equally to this work)
- 9) Depenni R, Cossu Rocca M, Ferrari D, Azzarello G, **Baldessari C**, Alù M, Nolè F, Codecà C, Boscolo G, Piccininni M, Cavaliere S, Bossi P. Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting. *Eur J Cancer*. 2019 Jul;115:4-12. doi: 10.1016/j.ejca.2019.03.022.
- 10) Vitale MG, **Baldessari C**, Milella M, Buti S, Militello AM, Di Girolamo S, Fornarini G, Perri G, Basso U, Maruzzo M, Porta C, Cosmai L, Pipitone S, Cerna K, Cascinu S, Sabbatini R. Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. *Clin Genitourin Cancer*. 2019 Oct;17(5):e903-e908. doi: 10.1016/j.clgc.2019.06.009.
- 11) Losi L, Bertolini F, Guaitoli G, Fabbiani L, Banchelli F, Ambrosini-Spaltro A, Botticelli L, Scurani L, **Baldessari C**, Barbieri F, Cascinu S, Maiorana A. Role of evaluating tumor-infiltrating lymphocytes, programmed death-1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma. *Int J Oncol*. 2019 Nov;55(5):1157-1164. doi: 10.3892/ijo.2019.4883
- 12) Salati M, **Baldessari C**, Bonetti LR, Messina C, Merz V, Cerbelli B, Botticelli A. NUT midline carcinoma: Current concepts and future perspectives of a novel tumour entity. *Crit Rev Oncol Hematol*. 2019 Dec;144:102826. doi: 10.1016/j.critrevonc.2019.102826.
- 13) Guaitoli G, **Baldessari C**, Maur M, Mussini C, Meschiari M, Barbieri F, Cascinu S, Bertolini F. Treating cancer with immunotherapy in HIV-positive patients: A challenging reality. *Crit Rev Oncol Hematol*. 2020 Jan;145:102836. doi: 10.1016/j.critrevonc.2019.102836.
- 14) Facchinetti F, Mazzaschi G, Barbieri F, Passiglia F, Mazzoni F, Berardi R, Proto C, Cecere FL, Pilotto S, Scotti V, Rossi S, Del Conte A, Vita E, Bennati C, Ardizzoni A, Cerea G, Migliorino MR, Sala E, Camerini A, Bearz A, De Carlo E, Zanelli F, Guaitoli G, Garassino MC, Ciccone LP, Sartori G, Toschi L, Dall'Olio FG, Landi L, Pizzuttillo EG, Bartoli G, **Baldessari C**, Novello S, Bria E, Cortinovis DL, Rossi G, Rossi A, Banna GL, Camisa R, Di Maio M, Tiseo M. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. *Eur J Cancer*. 2020 May;130:155-167. doi: 10.1016/j.ejca.2020.02.023.
- 15) Vitale MG, Pipitone S, Venturielli M, **Baldessari C**, Porta C, Iannuzzi F, Basso U, Scagliarini S, Zucali PA, Galli L, Rossetti S, Caserta C, Bracarda S, Iacovelli R, Masini C, Cortellini A, Di Girolamo S, Buti S, Fornarini G, Carrozza F, Santoni M, Caputo F, Giacquinta S, Balduzzi S, D'Amico R, Vitale G, Mighali P, Sabbatini R. Correlation Between Immune-related Adverse Event (irAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. *Clin Genitourin Cancer*. 2020 May 20:S1558-7673(20)30118-X. doi: 10.1016/j.clgc.2020.05.010. Online ahead of print.
- 16) Caffo O, Zagonel V, **Baldessari C**, Berruti A, Bortolus R, Buti S, Ceresoli GL, Donini M, Ermacora P, Fornarini G, Fratino L, Masi ni C, Massari F, Mosca A, Mucciarini C, Procopio G, Tucci M, Verri E, Zucali P, Buttigliero C. On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. *Ann Oncol*. 2020 Oct;31(10):1415-1416. doi: 10.1016/j.annonc.2020.06.005.

- 17) Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerts JGJV, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzuttilo P, Sala L, Occhipinti MA, Citarella F, Marco R, Torniai M, Cantini L, Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettoruti L, Antonuzzo L, Scodes S, Landi L, Guaitoli G, **Baldessari C**, et al. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. *Clin Lung Cancer*. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.clcc.2020.06.010.
- 18) Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzuttilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordini P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, **Baldessari C**, et al. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 . *Cancer Immunol Immunother*. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9.
- 19) Bersanelli M, Giannarelli D, De Giorgi U, Pignata S, Di Maio M, Verzoni E, Clemente A, Guadalupi V, Signorelli D, Tiseo M, Giusti R, Filetti M, Di Napoli M, Calvetti L, Cappetta A, Ermacora P, Zara D, Barbieri F, **Baldessari C**, et al. Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. *Ther Adv Med Oncol*. 2020 Nov 2;12:1758835920968463. doi: 10.1177/1758835920968463.
- 20) Brunelli M, Tafuri A, Cima L, Cerruto MA, Milella M, Zivi A, Buti S, Bersanelli M, Fornarini G, Vellone VG, Rebutti SE, Procopio G, Verzoni E, Bracarda S, Sabbatini R, **Baldessari C**, et al. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. *J Clin Pathol*. 2020 Nov 3;jclinpath-2020-207089. doi: 10.1136/jclinpath-2020-207089.
- 21) Salati M, Caputo F, **Baldessari C**, Galassi B, Grossi F, Dominici M, Ghidini M. IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting. *Cancers (Basel)*. 2020 Nov 9;12(11):E3310. doi: 10.3390/cancers12113310.
- 22) Aluisio G, Mazzeo E, Lohr F, Fiocchi F, Bettelli S, **Baldessari C**, Paterlini M, Bruni A. Unexpected tumor response to palliative pelvic radiotherapy in mismatch repair-deficient advanced prostate cancer: a case report. *J Med Case Rep*. 2020 Dec 8;14(1):239. doi: 10.1186/s13256-020-02578-4.
- 23) Pederzoli S, Spaggiari G, Bernardelli G, Mattioli F, **Baldessari C**, Maiorana A, Rochira V, Santi D. Gynecological malignancy mimicking a thyroid lymph node metastasis. *Endocrinol Diabetes Metab Case Rep*. 2021; 2021: 20-0055. Published online 2021 Jan 11. doi: 10.1530/EDM-20-0055
- 24) Cortellini A, De Giglio A, Cannita K, Cortinovis D L, Cornelissen R, **Baldessari C**, et al. Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. *Thorac Cancer*. 2021 Mar; 12(6): 880-889. Published online 2021 Feb 1. doi: 10.1111/1759-7714.13852
- 25) Nasso C, Sabbatini R, **Baldessari C**, Dominici M, Vitale MG. Long progression-free survival with cabozantinib in a heavily pre-treated patient with metastatic renal cell carcinoma: a case report. *Tumori*. 2021 Dec;107(6):NP33-NP36. doi: 10.1177/0300891621990732.
- 26) Cortellini A, Cannita K, Tiseo M, Cortinovis DL, Aerts JGJV, **Baldessari C**, et al. Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicentre real-world study. *Eur J Cancer*. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.
- 27) Fornarini G, Rebutti SE, Banna GL, Calabrò F, Scandurra G, De Giorgi U, Masini C, **Baldessari C**, et al. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort. *ESMO Open*. 2021 Jun;6(3):100118. doi: 10.1016/j.esmoop.2021.100118.
- 28) Rebutti S E, Signori A, Banna G L, Maruzzo M, De Giorgi U, Pedrazzoli P, Sbrana A, Zucali P A, Masini C, Naglieri E, Procopio G, Merler S, Tomasello L, Frattino L, **Baldessari C**, et al. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). *Ther Adv Med Oncol*. 2021; 13: 17588359211019642. Published online 2021 May 18. doi: 10.1177/17588359211019642. Correction in: *Ther Adv Med Oncol*. 2021; 13: 17588359211036552.

- 29) Bersanelli M, Giannarelli D, De Giorgi U, Pignata S, Di Maio M, Clemente A, Verzoni E, Giusti R, Di Napoli M, Aprile G, Ermacora P, Catino A, Scotti V, Mazzoni F, Guglielmini P F, Veccia A, Maruzzo M, Rossi E, Grossi F, Casadei C, Ficarella C, Montesarchio V, Verderame F, Rizzo M, Guaitoli G, Fratino L, Accettura C, Mencoboni M, Zustovich F, **Baldessari C**, et al, FICOG group (Federation of Italian Cooperative Oncology Groups). INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDia-2). *J Immunother Cancer*. 2021; 9(5): e002619. Published online 2021 May 20. doi: 10.1136/jitc-2021-002619
- 30) **Baldessari C**, Guaitoli G, Valoriani F, Bonacini R, Marcheselli R, Reverberi L, Pecchi A, Menozzi R, Torricelli P, Bertolini F, Barbieri F, Dominici M. Impact of body composition, nutritional and inflammatory status on outcome of non-small cell lung cancer patients treated with immunotherapy. *Clin Nutr ESPEN*. 2021 Jun;43:64-75. doi: 10.1016/j.clnesp.2021.02.017.
- 31) Canino F, Pugliese G, **Baldessari C**, Greco S, Depenni R, Dominici M. Cemiplimab- and nivolumab-induced myasthenia gravis: two clinical cases. *Tumori*. 2021 Dec;107(6):NP123-NP126. doi: 10.1177/03008916211040559.
- 32) Vitale MG, Nasso C, Oltrecolli M, **Baldessari C**, Fanelli M, Dominici M, Sabbatini R. Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma. *Expert Rev Anticancer Ther*. 2021 Nov;21(11):1183-1192. doi: 10.1080/14737140.2021.1971519.
- 33) **Baldessari C**, Pecchi A, Marcheselli R, Guaitoli G, Bonacini R, Valoriani F, Torricelli P, Reverberi L, Menozzi R, Pugliese G, Vitale MG, Sabbatini R, Bertolini F, Barbieri F, Dominici M. Body composition and inflammation impact in non-small-cell lung cancer patients treated by first-line immunotherapy. *Immunotherapy*. 2021 Dec;13(18):1501-1519. doi: 10.2217/imt-2021-0038.
- 34) Bersanelli M, Buti S, Rizzo M, Cortellini A, Cattrini C, Massari F, Masini C, Vitale M G, Fornarini G, Caffo O, Atzori F, Gatti A, Macrini S, Mucciarini C, Galli L, Morelli F, Stellato M, Fanelli M, Corti F, Zucali P A, Toscani I, Dalla Volta A, Gernone A, **Baldessari C**, et al. GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. *Ther Adv Urol*. 2021 Jan-Dec; 13: 17562872211054302. Published online 2021 Oct 22. doi: 10.1177/17562872211054302. Correction in: *Ther Adv Urol*. 2021 Jan-Dec; 13: 17562872211067689.
- 35) Salati M, Caputo F, **Baldessari C**, Carotenuto P, Messina M, Caramaschi S, Dominici M, Reggiani Bonetti L. The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting. *Cancer Manag Res*. 2021; 13: 7747–7757. Published online 2021 Oct 9. doi: 10.2147/CMAR.S330710
- 36) Pipitone S, Vitale MG, **Baldessari C**, Dominici M, Sabbatini R. Long survival of a young patient with Xp11.2 translocation metastatic clear cell renal carcinoma: case report. *Tumori*. 2021 Dec;107(6):NP131-NP135. doi: 10.1177/03008916211049275.
- 37) Banna G L, Tiseo M, Cortinovis D L, Facchinetti F, Aerts J G J V, **Baldessari C**, et al. Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 $\geq 50\%$ metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. *Thorac Cancer*. 2022 Feb; 13(3): 483–488. Published online 2021 Dec 22. doi: 10.1111/1759-7714.14256
- 38) **Baldessari C**, Pugliese G, Venturelli M, Greco S, Ferrara L, Longo G, Dominici M, Depenni R. Myocarditis and diaphragmatic rhabdomyolysis with respiratory failure in a patient with metastatic melanoma treated with Nivolumab. *J Oncol Pharm Pract*. 2021 Dec 29;10781552211067424. doi: 10.1177/10781552211067424. Online ahead of print.

Firma

Cinzia Baldessari



I hereby authorize the processing of my personal data pursuant to current Italian law and GDPR 2016/679 on privacy, D.Lgs 196/2003 and D.Lgs 101/2018.

Modena 05.08.2024